These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. French DD; Margo CE Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410 [TBL] [Abstract][Full Text] [Related]
14. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Zweifel SA; Engelbert M; Khan S; Freund KB Retina; 2009; 29(10):1527-31. PubMed ID: 19898185 [TBL] [Abstract][Full Text] [Related]
18. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Schaal S; Kaplan HJ; Tezel TH Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553 [TBL] [Abstract][Full Text] [Related]
19. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
20. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S Retina; 2008; 28(10):1395-9. PubMed ID: 18827737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]